摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione;urea | 1418205-95-4

中文名称
——
中文别名
——
英文名称
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione;urea
英文别名
——
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione;urea化学式
CAS
1418205-95-4
化学式
CH4N2O*C13H13N3O3
mdl
——
分子量
319.32
InChiKey
WIQXWGGQOFBMCX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.95
  • 重原子数:
    23
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    162
  • 氢给体数:
    4
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    尿素来那度胺正庚烷2,2,2-三氟乙醇乙酸乙酯 为溶剂, 反应 24.0h, 以10 mg的产率得到3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione;urea
    参考文献:
    名称:
    [EN] NOVEL CRYSTALLINE FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE
    [FR] NOUVELLES FORMES CRISTALLINES DE 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)PIPÉRIDINE-2,6-DIONE
    摘要:
    公开号:
    WO2013012485A3
点击查看最新优质反应信息

文献信息

  • Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
    申请人:AMPLIO PHARMA, LLC
    公开号:US10100032B2
    公开(公告)日:2018-10-16
    The invention relates to novel crystalline forms of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.
    本发明涉及 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型结晶形式,包括 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型脲共晶体;3-(4-氨基-l-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型没食子酸共晶体; 3-(4-氨基-l-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型没食子酸丙酯共晶体;以及 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮的新型 L-酒石酸共晶体。本发明描述了根据本发明各种实施方案制备的新型晶体的制备和表征。本发明还涉及含有新型结晶形式的药物组合物以及新型结晶形式的治疗用途。
  • Improving the Solubility of Lenalidomide via Cocrystals
    作者:Jia-Xi Song、Yan Yan、Jia Yao、Jia-Mei Chen、Tong-Bu Lu
    DOI:10.1021/cg500327s
    日期:2014.6.4
    An anticancer drug, lenalidomide, has low oral bioavailability (below 33%) due to its poor solubility in water. To improve its solubility, three cocrystals of lenalidomide with urea (1) and 3,5-dihydroxybenzoic acid (2, 3) were prepared. The structures of 1-3 were determined by single crystal X-ray diffraction, and they all form three-dimensional hydrogen-bonded frameworks between lenalidomide and the coformers. The apparent solubility value and intrinsic dissolution rate of lenalidomide in phosphate buffer of pH 6.8 have been improved after the formation of cocrystals. In addition, 2 and 3 can convert to each other under certain conditions.
  • NOVEL CRYSTALLINE FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE
    申请人:AMPLIO PHARMA, LLC
    公开号:US20140296291A1
    公开(公告)日:2014-10-02
    The invention relates to novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.
  • US9540341B2
    申请人:——
    公开号:US9540341B2
    公开(公告)日:2017-01-10
  • [EN] NOVEL CRYSTALLINE FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE<br/>[FR] NOUVELLES FORMES CRISTALLINES DE 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)PIPÉRIDINE-2,6-DIONE
    申请人:AMPLIO PHARMA LLC
    公开号:WO2013012485A3
    公开(公告)日:2013-04-25
查看更多

同类化合物

(1Z,3Z)-1,3-双[[((4S)-4,5-二氢-4-苯基-2-恶唑基]亚甲基]-2,3-二氢-5,6-二甲基-1H-异吲哚 鲁拉西酮杂质33 鲁拉西酮杂质07 马吲哚 颜料黄110 顺式-六氢异吲哚盐酸盐 顺式-2-[(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)甲基]-N-乙基-1-苯基环丙烷甲酰胺 顺-N-(4-氯丁烯基)邻苯二甲酰亚胺 降莰烷-2,3-二甲酰亚胺 降冰片烯-2,3-二羧基亚胺基对硝基苄基碳酸酯 降冰片烯-2,3-二羧基亚胺基叔丁基碳酸酯 阿胍诺定 阿普斯特降解杂质 阿普斯特杂质29 阿普斯特杂质27 阿普斯特杂质26 阿普斯特杂质 阿普斯特 防焦剂MTP 铝酞菁 铁(II)2,9,16,23-四氨基酞菁 酞酰亚胺-15N钾盐 酞菁锡 酞菁二氯化硅 酞菁 单氯化镓(III) 盐 酞美普林 邻苯二甲酸亚胺 邻苯二甲酰基氨氯地平 邻苯二甲酰亚胺,N-((吗啉)甲基) 邻苯二甲酰亚胺阴离子 邻苯二甲酰亚胺钾盐 邻苯二甲酰亚胺钠盐 邻苯二甲酰亚胺观盐 邻苯二亚胺甲基磷酸二乙酯 那伏莫德 过氧化氢,2,5-二氢-5-苯基-3H-咪唑并[2,1-a]异吲哚-5-基 达格吡酮 诺非卡尼 螺[环丙烷-1,1'-异二氢吲哚]-3'-酮 螺[异吲哚啉-1,4'-哌啶]-3-酮盐酸盐 葡聚糖凝胶G-25 苹果酸钠 苯酚,4-溴-3-[(1-甲基肼基)甲基]-,1-苯磺酸酯 苯胺,4-乙基-N-羟基-N-亚硝基- 苯基甲基2-脱氧-2-(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)-3-O-(苯基甲基)-4,6-O-[(R)-苯基亚甲基]-BETA-D-吡喃葡萄糖苷 苯二酰亚氨乙醛二乙基乙缩醛 苯二甲酰亚氨基乙醛 苯二(甲)酰亚氨基甲基磷酸酯 膦酸,[[2-(1,3-二氢-1,3-二羰基-2H-异吲哚-2-基)苯基]甲基]-,二乙基酯 胺菊酯